Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells

[1]  L. Butterfield,et al.  Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. , 1998, Cancer research.

[2]  A. Ribas,et al.  Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. , 1998, Journal of immunology.

[3]  A. Ribas,et al.  In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. , 1997, Human gene therapy.

[4]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[5]  S. Rafii,et al.  Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.

[6]  S. Rosenberg,et al.  Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases , 1997, The Journal of experimental medicine.

[7]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[8]  T. Wobbes,et al.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.

[9]  A. Ribas,et al.  Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. , 1997, Cancer research.

[10]  M. Lotze.  Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. , 1997, Annals of surgery.

[11]  J. Cormier,et al.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. , 1997, Journal of immunotherapy.

[12]  R. Locksley,et al.  Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.

[13]  Simon C Watkins,et al.  In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. , 1997, Journal of immunology.

[14]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[15]  M. Bevan,et al.  Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.

[16]  E. Gilboa,et al.  Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts , 1997, International journal of cancer.

[17]  L. Zitvogel,et al.  Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines , 1997, Stem cells.

[18]  S. Rosenberg,et al.  Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. , 1996, Cancer research.

[19]  T. Mak,et al.  Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo , 1996, European journal of immunology.

[20]  P. van Endert,et al.  Characterization of antigenic peptides presented by HLA‐B44 molecules on tumor cells expressing the gene MAGE‐3 , 1996, International journal of cancer.

[21]  J. Thompson,et al.  Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. , 1996, Journal of immunology.

[22]  C. Rooney,et al.  Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro , 1996, Journal of virology.

[23]  L. Zitvogel,et al.  IL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo a , 1996, Annals of the New York Academy of Sciences.

[24]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[25]  S. H. van der Burg,et al.  Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A*0201‐binding peptides from the Melan‐A/MART‐1 self antigen , 1996, European journal of immunology.

[26]  C. Waes,et al.  Immunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro , 1996 .

[27]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[28]  D. Scott,et al.  T cells commit suicide, but B cells are murdered! , 1996, Journal of immunology.

[29]  S. Chatterjee,et al.  Parvoviral vectors for the gene therapy of cancer. , 1996, Seminars in oncology.

[30]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[31]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.

[32]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[33]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[34]  K. Murphy,et al.  The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model , 1995, The Journal of experimental medicine.

[35]  R. Dutton,et al.  Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. , 1995, Journal of immunology.

[36]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[37]  E. Gilboa,et al.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[38]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[39]  D. Green,et al.  Activation-induced apoptosis in lymphocytes. , 1994, Current opinion in immunology.

[40]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[42]  R. Steinman,et al.  Identification of proliferating dendritic cell precursors in mouse blood , 1992, The Journal of experimental medicine.

[43]  P. Morris,et al.  Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues , 1988, The Journal of experimental medicine.

[44]  L. Milas,et al.  Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. , 1987, Cancer research.

[45]  M. Kripke,et al.  Antigenicity of murine skin tumors induced by ultraviolet light. , 1974, Journal of the National Cancer Institute.

[46]  S. Rosenberg,et al.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. , 1997, Journal of immunotherapy.

[47]  M. Roth,et al.  A comparison of gene transfer methods in human dendritic cells. , 1997, Cancer gene therapy.

[48]  C. Van Waes,et al.  Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. , 1996, Tissue antigens.

[49]  K. Hunt,et al.  In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. , 1996, Cancer gene therapy.

[50]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.